Publication:
Comparison of involved field radiotherapy versus elective nodal irradiation in stage IIIB/C non-small-cell lung carcinoma patients treated with concurrent chemoradiotherapy: a propensity score matching Study

dc.contributor.coauthorTopkan, Erkan
dc.contributor.coauthorÖzdemir, Yurday
dc.contributor.coauthorGüler, Ozan Cem
dc.contributor.coauthorKüçük, Ahmet
dc.contributor.coauthorBesen, Ali Ayberk
dc.contributor.coauthorMertsoylu, Hüseyin
dc.contributor.coauthorSezer, Ahmet
dc.contributor.coauthorPehlivan, Berrin
dc.contributor.departmentKUH (Koç University Hospital)
dc.contributor.departmentSchool of Medicine
dc.contributor.schoolcollegeinstituteKUH (KOÇ UNIVERSITY HOSPITAL)
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T12:14:01Z
dc.date.issued2020
dc.description.abstractBackground: we retrospectively compared the incidence of isolated elective nodal failure (IENF) and toxicity rates and survival outcomes after elective nodal irradiation (ENI) versus involved-field RT (IFRT) by employing the propensity score matching (PSM) methodology in stage IIIB/C inoperable non-small-cell lung cancer (NSCLC) patients treated with definitive concurrent chemoradiotherapy (C-CRT). Methods: our PSM examination included 1048 stage IIIB/C NSCLC patients treated with C-CRT from January 2007 to December 2016: a total dose of 66 Gy (2 Gy/fraction) radiotherapy and 1-3 cycles of platinum-based doublet chemotherapy concurrently. The primary and secondary endpoints were the IENF and toxicity rates and survival outcomes after ENI versus IFRT, respectively. Propensity scores were calculated for each group to adjust for confounding variables and facilitate well-balanced comparability by creating 1: 1 matched study groups. Results: the median follow-up was 26.4 months for the whole study accomplice. The PSM analysis unveiled 1: 1 matched 646 patients for the ENI (N = 323) and IFRT (N = 323) cohorts. Intergroup comparisons discovered that the 5-year isolated ENF incidence rates (3.4% versus 4.3%; P=0.52) and median overall survival (25.2 versus 24.6 months; P=0.69), locoregional progression-free survival (15.3 versus 15.1 months; P=0.52), and progression-free survival (11.7 versus 11.2 months; P=0.57) durations were similar between the ENI and IFRT cohorts, separately. However, acute grade 3-4 leukopenia (P=0.0012), grade 3 nausea-vomiting (P=0.006), esophagitis (P=0.003), pneumonitis (P=0.002), late grade 3-4 esophageal toxicity (P=0.038), and the need for hospitalization (P<0.001) were all significantly higher in the ENI than in the IFRT group, respectively. Conclusion: results of the present large-scale PSM cohort established the absence of meaningful IENF or survival differences between the IFRT and ENI cohorts and, consequently, counseled the IFRT as the elected RT technique for such patients since ENI increased the toxicity rates.
dc.description.fulltextYES
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipN/A
dc.description.versionPublisher version
dc.description.volume2020
dc.identifier.doi10.1155/2020/7083149
dc.identifier.eissn1687-8469
dc.identifier.embargoNO
dc.identifier.filenameinventorynoIR02417
dc.identifier.issn1687-8450
dc.identifier.quartileQ2
dc.identifier.scopus2-s2.0-85091414533
dc.identifier.urihttps://doi.org/10.1155/2020/7083149
dc.identifier.wos573041600003
dc.keywords3D-conformal radiotherapy
dc.keywordsConformal radiotherapy
dc.keywordsRadiation-therapy
dc.keywordsPhase-III
dc.keywordsCancer
dc.keywordsFailure
dc.keywordsIMRT
dc.keywordsEsophagitis
dc.keywordsCombination
dc.keywordsMetastasis
dc.language.isoeng
dc.publisherHindawi
dc.relation.grantnoNA
dc.relation.ispartofJournal of Oncology
dc.relation.urihttp://cdm21054.contentdm.oclc.org/cdm/ref/collection/IR/id/9053
dc.subjectMedicine
dc.subjectOncology
dc.titleComparison of involved field radiotherapy versus elective nodal irradiation in stage IIIB/C non-small-cell lung carcinoma patients treated with concurrent chemoradiotherapy: a propensity score matching Study
dc.typeJournal Article
dspace.entity.typePublication
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit1KUH (KOÇ UNIVERSITY HOSPITAL)
local.publication.orgunit2KUH (Koç University Hospital)
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isParentOrgUnitOfPublication055775c9-9efe-43ec-814f-f6d771fa6dee
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery055775c9-9efe-43ec-814f-f6d771fa6dee

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
9053.pdf
Size:
1.55 MB
Format:
Adobe Portable Document Format